Understanding how targeted radiation therapy can help men with early-stage metastatic prostate cancer
Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer
This study is looking at how well a specific type of radiation therapy works for men who have just been diagnosed with prostate cancer that has spread to a few places, and it aims to find out which patients might benefit the most from this treatment by using advanced imaging and blood tests.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10488573 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of metastasis-directed radiotherapy (MDT) for men diagnosed with de novo oligometastatic prostate cancer. It involves a phase 3 randomized controlled trial that collects imaging and biospecimens, such as tissue and blood samples, to identify which patients may benefit the most from this treatment. The study aims to develop predictive biomarkers that can help determine the likelihood of cure and treatment success for individual patients. By leveraging advanced imaging techniques and genomic analysis, the research seeks to provide personalized treatment options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with de novo oligometastatic prostate cancer who are eligible for metastasis-directed radiotherapy.
Not a fit: Patients with advanced metastatic prostate cancer or those who do not meet the criteria for oligometastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for men with oligometastatic prostate cancer.
How similar studies have performed: This approach is part of a larger international trial and builds on previous successes in targeted therapies, making it a promising avenue for further exploration.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Spratt, Daniel Eidelberg — Case Western Reserve University
- Study coordinator: Spratt, Daniel Eidelberg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.